Walgreens October Sales Decrease 2.1 Percent

  Walgreens October Sales Decrease 2.1 Percent

  Balance™ Rewards registrations reach more than 28 million through October

Business Wire

DEERFIELD, Ill. -- November 05, 2012

Walgreens (NYSE: WAG) (Nasdaq: WAG) had October sales of $6.00 billion, a
decrease of 2.1 percent from $6.13 billion for the same month in fiscal 2012.
Results include the impact of Hurricane Sandy through Oct. 31.

Total front-end sales decreased 1.5 percent compared with the same month in
fiscal 2012, while comparable store front-end sales decreased 2.9 percent
through Oct. 31. Customer traffic in comparable stores decreased 5.2 percent
while basket size increased 2.3 percent.

Chief Financial Officer and President, International Wade Miquelon said, “Our
strategic decision not to pursue unprofitable promotions resulted in solid
margins for the month as we continue to focus on gross profit dollar growth.”

Prescriptions filled at comparable stores decreased by 1.8 percent in October
and by a day-fall adjusted (DFA) 5.4 percent. This year’s October had one
additional Tuesday and Wednesday and one fewer Saturday and Sunday compared
with October 2011, positively impacting prescriptions filled in comparable
stores by 3.6 percentage points. DFA prescriptions filled at comparable stores
also were positively impacted by 0.2 percentage point due to the higher
incidence of flu in this year’s October. These results also include the storm

At the peak of the storm, approximately 750 of 1,400 stores in the impacted
area were closed. Nearly all of those locations have since reopened.

For the period from Oct. 1 through Oct. 25, which excludes the impact from
Hurricane Sandy, comparable store front-end sales decreased 2.4 percent, while
prescriptions filled at comparable stores decreased 4.6 percent, adjusted for
calendar shifts.

Click here for a graph showing the trend of comparable prescriptions filled
adjusted for day fall and flu impacts.

For the month through Oct. 31, pharmacy sales decreased 2.6 percent, while
comparable store pharmacy sales decreased 7.5 percent. Calendar day shifts
positively impacted pharmacy sales in comparable stores by 3.6 percentage
points. DFA comparable store pharmacy sales were negatively impacted by 9.0
percentage points due to generic drug introductions in the last 12 months.
Pharmacy sales accounted for 64.8 percent of total sales for the month.

Flu shots administered at pharmacies and clinics season-to-date were nearly
3.6 million versus approximately 4 million last year.

Sales in comparable stores decreased by 5.9 percent for the month through Oct.
31. Calendar day shifts positively impacted total comparable sales by 2.3
percentage points, while generic drug introductions in the last 12 months
negatively impacted total comparable sales by 5.8 percentage points.

Registrations for Walgreens Balance™ Rewards loyalty program, which launched
in September, totaled more than 28 million through Oct. 31.

Calendar year-to-date sales were $57.96 billion, a decrease of 3.6 percent
from $60.11 billion in 2011.

Fiscal 2013 year-to-date sales for the two months were $11.48 billion, down
4.9 percent from $12.07 billion in fiscal 2012.

Walgreens opened 21 stores during October, including five relocations.

At Oct. 31, Walgreens operated 8,489 locations in all 50 states, the District
of Columbia, Puerto Rico and Guam. That includes 8,030 drugstores, 244 more
than a year ago, including 108 net stores acquired over the last 12 months.
The company also operates infusion and respiratory services facilities,
specialty pharmacies and mail service facilities. Its Take Care Health Systems
subsidiary manages more than 700 in-store convenient care clinics and worksite
health and wellness centers.

                October Comparable Sales and Prescriptions Filled
                Actual                  Generics   Cough, Cold, Flu  Flu Shot
                         Calendar       Impact     Impact             Impact
                         Shift Impact
Total Comp      -5.9%    2.3%           -5.8%      -0.1%              0.0%
Comp Front      -2.9%    0.0%           -          -
Comp Rx Sales   -7.5%    3.6%           -9.0%      -0.2%              -0.1%
Comp Rx         -1.8%*   3.6%           -          0.2%               0.0%

* Includes +2.2 percentage points from patients filling more 90-day

Please note: Sales numbers and the adjustments shown in the table are
preliminary, unaudited and subject to revision. Comparable stores are defined
as those drugstore locations open for at least 12 consecutive months without
closure for seven or more consecutive days and without a major remodel or a
natural disaster in the past 12 months. Acquired operating locations and
relocations are not included as comparable stores for the first 12 months
after the acquisition or relocation.

Cautionary Note Regarding Forward-Looking Statements: Statements in this
release that are not historical are forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "expect," “likely,” "outlook," “forecast, "would,"
"could," "should," “can,” “will,” "project," "intend," "plan," "goal,”
“continue," "sustain," “synergy,” "on track," "believe," "seek," "estimate,"
"anticipate," "may," “possible,” "assume," and variations of such words and
similar expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance and
involve risks, assumptions and uncertainties, including, but not limited to,
those described in Item 1A (Risk Factors) of our most recent Annual Report on
Form 10-K, which is incorporated herein by reference, and in other documents
that we file or furnish with the Securities and Exchange Commission. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
indicated or anticipated by such forward-looking statements. Accordingly, you
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date they are made. Except to the extent required
by law, Walgreens does not undertake, and expressly disclaims, any duty or
obligation to update publicly any forward-looking statement after the date of
this report, whether as a result of new information, future events, changes in
assumptions or otherwise.

Photos/MultimediaGallery Available:



Media Contact:
Michael Polzin, 847-315-2920
Investor Contacts:
Rick Hans, CFA, 847-315-2385
Snehal Shah, 847-315-2361
Press spacebar to pause and continue. Press esc to stop.